RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00050348.xml
PDF herunterladen
CC BY 4.0 · Indian J Med Paediatr Oncol 2023; 44(01): 066-070
DOI: 10.1055/s-0042-1759715
DOI: 10.1055/s-0042-1759715
Review Article
Imaging Recommendations for Diagnosis, Staging, and Management of Gastric Cancer
Autoren
Abstract
Gastric cancer is the second most common cause of cancer-related death in Indian men and women aged between 15 and 44 years. Most patients present at an advanced stage of disease. Surgically resectable disease usually requires a standard gastric resection and D2 lymphadenectomy. Imaging, especially with computed tomography scan of abdomen as well as thorax, is necessary for localization, nodal mapping, and metastatic workup of gastric cancer. In this review, we discuss current imaging recommendations for gastric carcinoma.
Publikationsverlauf
Artikel online veröffentlicht:
06. März 2023
© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Servarayan Murugesan C, Manickavasagam K, Chandramohan A. et al. Gastric cancer in India: epidemiology and standard of treatment. Updates Surg 2018; 70 (02) 233-239
- 2 Compare D, Rocco A, Nardone G. Risk factors in gastric cancer. Eur Rev Med Pharmacol Sci 2010; 14 (04) 302-308
- 3 Fock KM, Talley N, Moayyedi P. et al; Asia-Pacific Gastric Cancer Consensus Conference. Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol 2008; 23 (03) 351-365
- 4 Ramakrishna BS. Helicobacter pylori infection in India: the case against eradication. Indian J Gastroenterol 2006; 25 (01) 25-28
- 5 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (06) 394-424
- 6 GBD 2017 Stomach Cancer Collaborators. The global, regional, and national burden of stomach cancer in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease study 2017. Lancet Gastroenterol Hepatol 2020; 5 (01) 42-54
- 7 ICMR Subcommittee on Gastric Cancer. ICMR: Consensus Document for Management of Gastric Cancer. Indian Council of Medical Research, editor. ICMR Subcommittee on Gastric Cancer. Indian Council of Medical Research; 2014;1–75
- 8 Awiwi MO, Ramanan RV, Elshikh M, Vikram R. Imaging of gastric carcinoma. part one: diagnosis and staging. J Gastrointest Abdom Radiol. 2021; 4 (03) 194-205
- 9 Leake PA, Cardoso R, Seevaratnam R. et al. A systematic review of the accuracy and indications for diagnostic laparoscopy prior to curative-intent resection of gastric cancer. Gastric Cancer 2012; 15 (Suppl 1): S38-S47
- 10 National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology [Internet]. [cited 2020 Nov 6]. Accessed November 17, 2022, at: https://www.nccn.org/professionals/physician_gls
- 11 Leung WK, Wu MS, Kakugawa Y. et al; Asia Pacific Working Group on Gastric Cancer. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol 2008; 9 (03) 279-287
- 12 Hamashima C. Systematic Review Group and Guideline Development Group for Gastric Cancer Screening Guidelines. Update version of the Japanese Guidelines for Gastric Cancer Screening. Jpn J Clin Oncol 2018; 48 (07) 673-683
- 13 Kelly S, Harris KM, Berry E. et al. A systematic review of the staging performance of endoscopic ultrasound in gastro-oesophageal carcinoma. Gut 2001; 49 (04) 534-539
- 14 Findlay JM, Antonowicz S, Segaran A. et al. Routinely staging gastric cancer with 18F-FDG PET-CT detects additional metastases and predicts early recurrence and death after surgery. Eur Radiol 2019; 29 (05) 2490-2498
- 15 Yang YT, Dong SY, Zhao J, Wang WT, Zeng MS, Rao SX. CT-detected extramural venous invasion is corelated with presence of lymph node metastasis and progression-free survival in gastric cancer. Br J Radiol 2020; 93 (1116): 20200673
- 16 Ferlay J, Soerjomataram I, Dikshit R. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136 (05) E359-E386
- 17 Maru P, Roy B, Sen S, Chatterjee A. Imaging of gastric carcinoma. part two: lymph node mapping in gastric carcinoma. J Gastrointest Abdomin Radiol 2021; 4 (03) 206-213
- 18 Beer AJ, Wieder HA, Lordick F. et al. Adenocarcinomas of esophagogastric junction: multi-detector row CT to evaluate early response to neoadjuvant chemotherapy. Radiology 2006; 239 (02) 472-480
- 19 Hopkins S, Yang GY. FDG PET imaging in the staging and management of gastric cancer. J Gastrointest Oncol 2011; 2 (01) 39-44
- 20 Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer 2021; 24 (01) 1-21
- 21 Sugarbaker PH, Van der Speeten K. Adjuvant HIPEC for gastric cancer. J Gastrointest Oncol 2021; 12 (Suppl 1): S18-S19
- 22 Fujitani K, Yang HK, Mizusawa J. et al; REGATTA study investigators. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol 2016; 17 (03) 309-318
- 23 Al-Batran SE, Homann N, Pauligk C. et al; FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019; 393 (10184): 1948-1957
- 24 Janjigian YY, Kawazoe A, Yanez PE. et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study. J Clin Orthod 2021; 39 (15, suppl): 4013-4013
- 25 Janjigian YY, Shitara K, Moehler M. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 2021; 398 (10294): 27-40
- 26 Bang YJ, Van Cutsem E, Feyereislova A. et al; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376 (9742): 687-697
- 27 Janjigian YY, Maron SB, Chatila WK. et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncol 2020; 21 (06) 821-831